Delivers Strong Results Across Key Metrics
GAAP Operating Margin and Diluted EPS Lower; Adjusted Operating Margin and Adjusted Diluted EPS Both up Sharply vs. Year-Ago Quarter
Full-Year Guidance Increased
KANSAS CITY, Mo., Oct. 29, 2021 (GLOBE NEWSWIRE) — Cerner Corporation (Nasdaq: CERN) today announced results for the 2021 third quarter that ended September 30, 2021.
The third quarter 2021 earnings release can be viewed here as well as on the company’s website at https://investors.cerner.com/financial-releases.
Cerner will host an earnings conference call to provide additional detail on the Company’s results and outlook at 8:00 a.m. CT on October 29, 2021. On the call, Cerner will discuss its results and answer questions from the investment community. The call may also include discussion of Cerner developments, and forward-looking and other material information about business and financial matters. The dial-in number for the conference call is (678) 509-7542; the passcode is Cerner. Cerner recommends joining the call 15 minutes early for registration.
An audio webcast will be available live and archived on the Investor Relations page of Cerner’s website at https://investors.cerner.com/events-and-presentations.
What: Cerner Third Quarter 2021 Earnings Conference Call Webcast
When: Friday, October 29, 2021
Time: 8:00 a.m. Central Time
Financial Results: https://investors.cerner.com/financial-releases
Webcast: https://investors.cerner.com/events-and-presentations
Investor Contact: Allan Kells, (816) 201-2445, akells@cerner.com
Media Contact: Stephanie Greenwood, Stephanie.Greenwood@cerner.com
Toronto, Ontario--(Newsfile Corp. - December 27, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…
RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ:…
CHONGQING, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired…
MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases…
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without…
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…